Download: Where are we now with US payers on biosimilars pricing, uptake and reimbursement?


sandoz, biosimilars, market access, pricing, reimbursement, aca reform, market access usa



At the Market Access World USA conference held last October 17th in Boston, Ken Walsh, Global Pricing & Market Access, Sandoz Biopharmaceuticals gave a presentation on "Where are We Now with US Payers on Biosimilars Pricing, Uptake and Reimbursement?" 

In the presentation, he discusses biosimilars today in the US in light of BCPA / ACA reform, and future launches in the USA.

The presentation covers:

  • Biosimilar pathway: upsides and downsides after release of draft guidelines
  • The ACA Established Medicare Part B Payment for Biosimilars
  • Omnitrope in the USA: Serves as a critical lesson for future pharmacy benefit biosimilar launches
  • Patient access has the potential to be enhanced: UK Filgrastim market
  • Enhanced competition from the introduction of biosimilars: German EPO market all players lower list prices

Download presentation

To learn more about ACA reform, join us at Market Access USA, where Dr Jacob Drapkin, Vice President Reimbursement & Healthcare Economics, Johnson & Johnson will be speaking on "Why you should care about the impact of the ACA on the employer."

Download the brochure for the full agenda and speaker list

Leave a Reply

Your email address will not be published. Required fields are marked *